symbiosis
Bacteria We Need Them to Survive!
There's no ignoring that we have a symbiotic relationship with microbes that live on our person
The Managed Care-Pharma Interface-Part IV: Post-Marketing Facilitation
Raymond V. Gilmartin, the former Chairman, President and Chief Executive Officer of Merck & Co., Inc. (1994-2005) in a speech January 19, 2000 gave commentary about the Pharmaceutical and Medicine Manufacturing (PMM) industry that I continue to dissect (See "Part III: the Pitfalls and the Promise" (last week). My objective is to get to synergism between the PMM industry and health care: (Cont'd)
The Managed Care-Pharma Interface-Part II: the Tension
As stated in the inaugural issue of this blog, the interface between managed care and the Pharmaceutical and Medicine Manufacturing (PMM) industries, is vital. They have in common the issues of appropriateness, compliance, cost-effectiveness, patient selection and symbiosis among all relevant players on the health care stage (ACCESS).
I say, put the practicing clinician on the PMM team and visa versa—How and Why?
The Managed Care-Pharma Interface-Part I: The Issues
The issues of appropriateness, compliance, cost-effectiveness, patient selection and symbiosis (ACCESS) are vital to both health care and pharmaceutical industries and define their possible relationship.
